GlassScriptPhysician profile
Ashley Holt
NPI 1972815702
$19,029.81
in general payments reported to CMS, 2019-2025
67 companies · $4,592 in 2025
The $4,592 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,382 · 2022: $3,897 · 2023: $3,135 · 2024: $4,024 · 2025: $4,592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,750.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,396.89 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $2,438.49 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Novartis Pharmaceuticals Corporation | $1,670.03 | 2021-2025 | |
| Pfizer INC. | $962.92 | 2021-2025 | |
| Lundbeck LLC | $738.08 | 2021-2025 | Vyepti, Rexulti |
| Ucb, INC. | $709.72 | 2021-2025 | Nayzilam, Rystiggo, Briviact |
| Lilly USA, LLC | $665.64 | 2023-2025 | Amyvid, Emgality, Kisunla |
| Biohaven Pharmaceutical Holding Company LTD. | $647.60 | 2022 | |
| Emd Serono, INC. | $609.81 | 2021-2025 | Mavenclad |
| Biohaven Pharmaceuticals, INC. | $602.71 | 2021 | |
| Biogen, INC. | $583.02 | 2021-2025 | Vumerity, Tysabri, Spinraza |
| Eisai INC. | $581.80 | 2022-2025 | |
| Neurocrine Biosciences, INC. | $506.45 | 2021-2025 | Ingrezza |
| Banner Life Sciences, LLC | $309.42 | 2022-2024 | |
| Celgene Corporation | $285.97 | 2022-2025 | Zeposia |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Holt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.